Who Paid My Doc
Sathya Velkuru
Walnut, CA Doctor of Osteopathy
NPI 1689068587 CMS profile 5697848
21010 Stoddard Wells Rd, Walnut, CA 91789
General payments
$996
Research payments
$0
Ownership & investment interest
$0
Through program year 2020, Sathya Velkuru of Walnut, CA is reported in the CMS Open Payments database as having received $996 across 46 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $103 | 4 | |
| 2019 | General | $893 | 42 |
Beside peers
- Sathya Velkuru
- California median
- Middle half of California
- National median
In program year 2025, general payments to Sathya Velkuru were reported at $0. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.
Show as a table
| Year | Sathya Velkuru | California median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $893 | $161 | $50–$652 | $163 |
| 2020 | $103 | $114 | $34–$392 | $114 |
| 2021 | $0 | $137 | $41–$509 | $132 |
| 2022 | $0 | $152 | $48–$573 | $149 |
| 2023 | $0 | $162 | $50–$581 | $160 |
| 2024 | $0 | $162 | $52–$583 | $164 |
| 2025 | $0 | $172 | $54–$610 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 36 drugsPart D claims
2,233
Drug cost
$2,284,802
Branded share of claims
50.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xeljanz Tofacitinib Citrate | Brand | 126 | $435,984 | |
| Enbrel Etanercept | Brand | 85 | $413,850 | |
| Enbrel Sureclick Etanercept | Brand | 58 | $284,093 | |
| Orencia Clickject Abatacept | Brand | 47 | $215,348 | |
| Amjevita(Cf) Autoinjector Adalimumab-Atto | Brand | 159 | $193,674 | |
| Actemra Actpen Tocilizumab | Brand | 48 | $124,222 | |
| Orencia Abatacept | Brand | 22 | $101,009 | |
| Humira Adalimumab | Brand | 12 | $84,009 | |
| Tyenne Autoinjector Tocilizumab-Aazg | Brand | 40 | $83,749 | |
| Cosentyx Sensoready (2 Pens) Secukinumab | Brand | 25 | $81,368 |
The 10 drugs with the highest cost, of 36 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.
Records
46 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.